Skip to content
KO·EN
Contact

DRAFT TRANSLATION · REVIEW PENDING

INVESTMENT OUTLOOK

INVESTOR RELATIONS · HAEPAGEN

GROWTH & RETURN OUTLOOK

Investment return outlook driven by HAEPAGEN's growth

Investment Return Outlook Driven by HAEPAGEN's Growth

01

Cosmetic Ingredient Business Growth

Expanding revenue and building a stable profit structure

02

Shareholder Value Realization

Providing investment returns through a dividend policy

03

Pharmaceutical Ingredient Commercialization

Entering the high-value biomaterials market

04

Global Investment Attraction

Expanding overseas capital and strategic partnerships

05

Enterprise Value Growth and Investment Returns

Targeting an expected enterprise value of KRW 300–500 billion

HAEPAGEN

English corporate copy is awaiting content approval.

Contact →
COMPANYCEO MESSAGE
R&DCORE TECHNOLOGYPRODUCTION INFRASTRUCTUREPATENTS
BUSINESS
ESG
IRGLOBAL RESOURCES
PR